View PDF Version - RePub - Erasmus Universiteit Rotterdam
View PDF Version - RePub - Erasmus Universiteit Rotterdam
View PDF Version - RePub - Erasmus Universiteit Rotterdam
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Chapter 2.3<br />
76<br />
13. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in<br />
epidemiology. Epidemiology 2000;11:550-60.<br />
14. Mazumdar M, Smith A, Bacik J. Methods for categorizing a prognostic variable in a multivariable<br />
setting. Stat Med 2003;22:559-71.<br />
15. SAS. SAS Institute Inc. The GENMOD Procedure. In: SAS, ed. 9.2 ed, 2008.<br />
16. EASL Clinical Practice Guidelines. Management of chronic hepatitis B. European Association<br />
For The Study Of The Liver. J Hepatol 2009;50:227-42.<br />
17. ter Borg MJ, van Zonneveld M, Zeuzem S, Senturk H, Akarca US, Simon C, Hansen BE,<br />
Haagmans BL, de Man RA, Schalm SW, Janssen HL. Patterns of viral decline during PEGinterferon<br />
alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment<br />
response. Hepatology 2006;44:721-7.<br />
18. ter Borg MJ, Hansen BE, Herrmann E, Zeuzem S, Cakaloglu Y, Karayalcin S, Flisiak R, van’ t<br />
Veen A, de Man RA, Schalm SW, Janssen HL, Haagmans BL. Modelling of early viral kinetics<br />
and pegylated interferon-alpha2b pharmacokinetics in patients with HBeag-positive<br />
chronic hepatitis B. Antivir Ther 2007;12:1285-94.<br />
19. Dahari H, Shudo E, Ribeiro RM, Perelson AS. Modeling complex decay profi les of hepatitis B<br />
virus during antiviral therapy. Hepatology 2009;49:32-8.<br />
20. Flink HJ, Buster EH, Merican I, Nevens F, Kitis G, Cianciara J, de Vries RA, Hansen BE, Schalm<br />
SW, Janssen HL. Relapse after treatment with peginterferon alpha-2b alone or in combination<br />
with lamivudine in HBeAg positive chronic hepatitis B. Gut 2007;56:1485-6.<br />
21. Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G, Luo KX, Paik SW, Liaw<br />
YF, Button P, Popescu M. HBeAg and hepatitis B virus DNA as outcome predictors during<br />
therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology<br />
2008;47:428-34.<br />
22. Janssen HL, Buster EH. Comments on the EASL practice guidelines for the management of<br />
chronic hepatitis B: controversies in interferon-based therapy. J Hepatol 2009;51:224-6.<br />
23. Cooksley WG, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T, Chutaputti A,<br />
Chang WY, Zahm FE, Pluck N. Peginterferon alpha-2a (40 kDa): an advance in the treatment<br />
of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003;10:298-305.